Boston Scientific Corporation $BSX Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC reduced its position in shares of Boston Scientific Corporation (NYSE:BSX) by 5.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 172,495 shares of the medical equipment provider’s stock after selling 10,062 shares during the period. HighTower Advisors LLC’s holdings in Boston Scientific were worth $16,447,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in BSX. Claret Asset Management Corp raised its holdings in Boston Scientific by 4.4% in the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after acquiring an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC raised its holdings in Boston Scientific by 5.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after acquiring an additional 103 shares in the last quarter. Outfitters Financial LLC raised its holdings in Boston Scientific by 0.5% in the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock valued at $2,291,000 after acquiring an additional 110 shares in the last quarter. Fayez Sarofim & Co raised its holdings in Boston Scientific by 2.1% in the third quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock valued at $520,000 after acquiring an additional 111 shares in the last quarter. Finally, Natural Investments LLC raised its holdings in Boston Scientific by 2.9% in the fourth quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock valued at $384,000 after acquiring an additional 112 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Several Boston Scientific directors bought shares this week, including Cheryl Pegus, David C. Habiger, and Edward J. Ludwig. Heavy insider buying often signals management confidence and can help support sentiment around BSX. Article Title
• Positive Sentiment: Boston Scientific’s board authorized a $5 billion share repurchase program, which can be viewed as a sign that management believes the stock may be undervalued and could provide downside support. Article Title
• Positive Sentiment: Boston Scientific recently reported earnings and revenue that slightly beat expectations and raised guidance for 2026, reinforcing the company’s longer-term growth story even though the stock has remained weak.
• Neutral Sentiment: Recent analyst commentary has been mixed: firms like Baird and Stifel still have positive ratings, but several price targets were trimmed, suggesting Wall Street remains constructive while tempering expectations. Article Title
• Negative Sentiment: Coverage asking why BSX is down 13% since its last earnings report highlights lingering investor concern that the stock has not kept pace with its fundamentals, likely weighing on near-term trading. Article Title

Analyst Ratings Changes

BSX has been the topic of several recent analyst reports. Evercore cut their price target on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Wells Fargo & Company cut their price target on shares of Boston Scientific from $94.00 to $75.00 and set an “overweight” rating on the stock in a report on Thursday, April 23rd. Oppenheimer set a $90.00 price target on shares of Boston Scientific in a report on Thursday, April 23rd. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Finally, JPMorgan Chase & Co. cut their price target on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $92.71.

Boston Scientific Stock Up 1.0%

Shares of NYSE:BSX opened at $57.71 on Friday. The stock has a market capitalization of $85.77 billion, a price-to-earnings ratio of 24.15, a price-to-earnings-growth ratio of 1.06 and a beta of 0.62. Boston Scientific Corporation has a 1-year low of $52.52 and a 1-year high of $109.50. The company’s fifty day moving average is $61.97 and its two-hundred day moving average is $80.25. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific declared that its board has approved a stock repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig bought 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 9,800 shares of company stock valued at $554,012. Company insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.